ARVINAS, INC. (ARVN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$87.3M
Cash & Equivalents
$69.2M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$534M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase2 Readout | — |
| 2026-12-04 | Phase1 Readout | — |
| 2026-12-30 | Phase3 Readout | — |
| 2026-12-30 | Phase2 Readout | — |
| 2026-12-31 | Phase2 Readout | — |
Active Clinical Trials (9)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | PHASE3 | Active Not Recruiting | 59 |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic... | PHASE3 | Active Not Recruiting | 624 |
| NCT06206837 | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | PHASE2 | Active Not Recruiting | 71 |
| NCT05573555 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Adva... | PHASE2 | Active Not Recruiting | 20 |
| NCT07023731 | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | PHASE2 | Active Not Recruiting | 159 |
| NCT05548127 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Adva... | PHASE2 | Active Not Recruiting | 37 |
| NCT06125522 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Adva... | PHASE2 | Active Not Recruiting | 11 |
| NCT05463952 | A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic ... | PHASE1 | Active Not Recruiting | 6 |
| NCT07231991 | A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function | PHASE1 | Recruiting | 24 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.